The effect of a new breath actuated dry powder inhaler, the Turbuhaler*, was found to be reduced at inhalations slower than 28 I/minute. This flow rate could be generated by virtually all children aged >6 years, by 42 of 57 children <6 years (74%), and by six of 15 preschool children with acute wheeze (40%).
STUDY 1-MODES OF INHALATION
Ten boys and four girls, aged 7 to 15 years (mean 10 years), participated in the study. All suffered from chronic or episodic wheeze associated with an increase in forced expiratory volume in one second (FEV,) of at least 20% after one puff of terbutaline. All received regular inhaled treatment with 12 stimulants, 12 received inhaled corticosteroids, and three slow release theophylline. The study was approved by the ethics committee of Northern Jutland, and informed consent was obtained from all children and their parents.
The design was that of a randomised, controlled double blind, double dummy crossover study. Each child participated on two separate occasions at the same time of the day. One day *The Turbuhaler is known as the Turbohaler in the United Kingdom. terbutaline was inhaled as fast as possible and another day at inspiratory flow rates around 22 1/minute. When the results from these two days had been analysed the children participated for another two days, one at inspiratory flow rates around 30 1/minute and one at inspiratory flow rates around 101/minute (randomised sequence). On each study day the children always inhaled from two different Turbuhalers, one containing terbutaline and one placebo. Different flow rates were used with the two inhalers to ensure the blinding of the study.
On all four days the children inhaled as deeply as possible from residual volume and the breath was held for 10 seconds after the inhalation.
To evaluate if maximum bronchodilation had been achieved by the inhaler treatment the children inhaled four puffs of terbutaline (1 mg) from a pressurised aerosol with a Nebuhaler (Astra) at the end of each study day. Pulmonary functions were repeated 30 minutes after this treatment.
Before each visit, treatment with inhaled corticosteroids was stopped for 48 hours and treatment with 12 agonists and theophylline for 12 hours.
To be included in the study, pretreatment FEV, had to be s-70% of the predicted value or show a total increase e35% on each study day. Furthermore, a study on each child was only performed if the baseline FEV, was within 15% of its value on the first study day, and if this was not the case the child was asked to make a further visit on another day. The Therefore, the comparison between the four treatments took place on the steep part of the dose-response curve where differences are detected more easily than if maximum bronchodilation had been achieved by the Turbuhaler treatment. Under these conditions it was found that the effect of the Turbuhaler was retained down to inspiratory flow rates around 30 1/minute whereas inspiratory flow rates from 30 I/minute and downwards were associated with a decreasing response. This is in good accordance with the results of various in vitro studies showing that although the dose delivered from the Turbuhaler does not vary with flow rate, the amount of respirable drug particles (<5 ,u) decreases with decreasing flow rate so that the amount of particles <5 1t is about 50% lower at flow rates around 22 1/minute as compared with flow rates around 60 1/minute (Astra, personal communication). Therefore, the reduced effect at low inspiratory flow rates seems to be due to insufficient breaking up of the large drug particles in the mouthpiece insert due to insufficient energy supply from the inspiration. We do not know exactly at which flow rate the Turbuhaler will stop working but it still retained about 33% of its effect at flow rates around 13 1/minute, which is well beyond the lowest flow rate measured in any of the 265 normal children and most of the 34 asthmatic children with acute wheeze. For comparison the Rotahaler (Allen and Hanburys) has earlier been found to retain only about 10% of its maximum effect at inspiratory flow rates around 40 1/minute-a flow rate that about a quarter of children younger than 6 years could not generate. ' Our findings showed that children should be taught to inhale as fast as possible when using the Turbuhaler. Such advice is simple and, due to the rather high resistance of the inhaler, will not result in unacceptably rapid inspiratory flow rate, which would increase the likelihood of a more central deposition of drug in the bronchial tree.3 4 Virtually all children :6 years were able to generate an inspiratory flow rate of 30 I/minute, indicating that they would all be able to benefit optimally from Turbuhaler treatment. About a quarter of children aged 3-5 years, however, could not generate this inspiratory flow rate under basic conditions. Further, this number was even higher during attacks of acute bronchoconstriction or in periods of poor control of symptoms. Therefore it will be necessary to increase the inhaled dose or to use other inhalation devices in such situations in the younger age groups. This is in accordance with the recommendations with other powder inhalers,' 2 though there seem to be differences between the various inhalers in their susceptibility to a reduced inspiratory flow rate and critical flow rate beyond which the inhaler will not work at all.5
A reduction in inhaled volume of 0-5 1 has earlier been found not to affect the response from Turbuhaler treatment.6 Therefore, it is most unlikely that the small difference in inhaled volume between treatments at inspiratory flow rates around 22 1/minute and treatments at higher flow rates influenced the results in the present study.
We conclude that asthmatic children using a Turbuhaler should be taught to inhale as quickly as possible. Young children may gain less benefit from the treatment because they cannot generate sufficiently high inspiratory flow rates through this inhaler, especially during episodes of acute bronchoconstriction. This may also be the case for a few older children during episodes of severe wheeze. 
